Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections

Nivoix, Yasmine; Zamfir, Alina D.; Lutun, P.; Kara, Ferit; Remy, Véronique; Lioure, Bruno; Rigolot, J.C.; Entz‐Werlé, Natacha; Letscher-Bru, Valérie; Waller, J.; Levêque, Dominique; Koffel, Jean-Claude; Beretz, L.; Herbrecht, Raoul

doi:10.1016/j.jinf.2005.01.006

Cited by 48 publications

(35 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[38][39][40][41][42] The preliminary clinical experience with secondary combination antifungal therapy in patients who had failed to respond to single primary antifungal therapy has also been encouraging. 11,12,43 In agreement with a study by Cuenca-Estrella et al, 7 that showed indifferent antifungal effect for combinations of amphotericin B and triazoles agents, antifungal combinations with CAP, especially those with CAP plus voriconazole were associated with synergistic activity against itraconazole-resistant clinical A. fumigatus isolates. In our study, most patients in HD-and SD-arm received CAP in combination with voriconazole or AmBisome.…”

Section: Discussionsupporting

confidence: 82%

High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation

Safdar

Rodriguez

Rolston

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation

Safdar

Rodriguez

Rolston

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Laboratory data demonstrated additive-to-synergistic effects against A. fumigatus with the combination of caspofungin and AmB-d or itraconazole [158]. In vitro studies [163], some animal trials [164,165] and few human reports suggest that the association of triazoles and echinocandin could improve the mortality rate in IA [166][167][168][169][170][171]. However, further clinical studies with combined therapy are needed before the concept can be validated.…”

Section: Combination Therapymentioning

confidence: 99%

Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

Bulpa¹,

Dive²,

Sibille³

2007

European Respiratory Journal

313

200

View full text Add to dashboard Cite

Aspergillus spp. cultured in specimens from the airways of chronic obstructive pulmonary disease (COPD) patients are frequently considered as a contaminant. However, growing evidence suggests that severe COPD patients are at higher risk of developing invasive pulmonary aspergillosis (IPA), although IPA incidence in this population is poorly documented. Some data report that COPD is the underlying disease in 1% of patients with IPA.Definitive diagnosis of IPA in COPD patients is often difficult as tissue samples are rarely obtained before death. Diagnosis is therefore usually based on a combination of clinical features, radiological findings (mostly thoracic computed tomography scans), microbiological results and, sometimes, serological information.Of 56 patients with IPA reported in the literature, 43 (77%) were receiving corticosteroids on admission to hospital. Breathlessness was always a feature of disease and excess wheezing was present in 79% of patients. Fever (.38uC) was present in only 38.5%. Chest pain and haemoptysis were uncommon. Six out of 33 (18%) patients had tracheobronchitis observed during bronchoscopy. The median delay between symptoms and diagnosis was 8.5 days. The mortality rate was high: 53 out of 56 (95%) patients died despite invasive ventilation and antifungal treatment in 43 (77%) of them.In chronic obstructive pulmonary disease patients, invasive pulmonary aspergillosis currently carries a very poor prognosis. Outcome could perhaps be improved by more rapid diagnosis and prompt therapy with voriconazole.

show abstract

“…These drugs have been tested in the laboratory against a wide range of pathogenic fungi to determine their therapeutic efficacy, and interpretive breakpoints have been established or proposed for a few pathogenic yeasts (20,41,42). Current practices are evolving to use the newer drugs in combinations either with or after a more established therapeutic regimen for the treatment of serious yeast infections (18,26,35,37,43,50). Potential benefits of using these antifungal drugs in combinations against serious infections include a broader spectrum, reduced toxicity, lower likelihood of the emergence of acquired resistance, and synergistic or additive interactions (7,15,19,24,28,33).…”

mentioning

confidence: 99%

“…and candidiasis (35,37,43,48). Additionally, there are several reports of the use of antifungal combinations for the treatment of recalcitrant infections caused by yeast pathogens (17,30,46).…”

mentioning

confidence: 99%

Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans , Candida glabrata , and Candida parapsilosis

Chaturvedi

Ramani

Andes

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections

Cited by 48 publications

References 19 publications

High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation

High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation

Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans , Candida glabrata , and Candida parapsilosis

Contact Info

Product

Resources

About